| Literature DB >> 32430062 |
Calvin Jephcote1,2, David Brown3, Thomas Verbeek3, Alice Mah3.
Abstract
BACKGROUND: The petrochemical industry is a major source of hazardous and toxic air pollutants that are recognised to have mutagenic and carcinogenic properties. A wealth of occupational epidemiology literature exists around the petrochemical industry, with adverse haematological effects identified in employees exposed to 'low' concentrations of aromatic hydrocarbons (benzene, toluene, ethylbenzene, and xylene). Releases from the petrochemical industry are also thought to increase the risk of cancer incidence in fenceline communities. However, this emerging and at times inconclusive evidence base remains fragmented. The present study's aim was to conduct a systematic review and meta-analysis of epidemiological studies investigating the association between incidences of haematological malignancy and residential exposure to the petrochemical industry.Entities:
Keywords: Cancer; Environmental justice; Haematological; Leukaemia; Lymphoma; Meta-analysis; Myeloma; Petrochemical; Refinery
Mesh:
Substances:
Year: 2020 PMID: 32430062 PMCID: PMC7236944 DOI: 10.1186/s12940-020-00582-1
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
The different haematological malignancies
| Condition | Definition [ | Global incidence per annum [ | Global mortalities per annum [ | ||
|---|---|---|---|---|---|
| Count | ASR | Count | ASR | ||
| Leukaemia | A type of cancer that develops in blood-forming tissue, normally the bone marrow, resulting in the production of abnormal white blood cells which crowd out normal blood cells and platelets. | 437,033 | 5.2 | 309,006 | 3.5 |
| Hodgkin’s Lymphoma | A cancer of the lymphatic system, a large network of nodes and vessels that carries tissue fluid (called lymph) throughout the body and an important element of the immune system. | 79,990 | 1 | 26,167 | 0.3 |
| Non-Hodgkin’s Lymphoma | A cancer of the lymphatic system. | 509,590 | 5.7 | 248,724 | 2.8 |
| Multiple Myeloma | A cancer of plasma cells, a type of white blood cells that produce antibodies, which collects in the bone marrow, the soft fatty tissue inside bone cavities. | 159,985 | 1.8 | 106,105 | 1.1 |
Age-standardized rates (ASRs) per 100,000 persons
Fig. 1PRISMA flowchart of the systematic literature search on haematological malignancy incidence in residents living near petrochemical facilities
A summary of the studies identified by the systematic review for inclusion in the meta-analysis models (based on design, survey resolution and the demographics of fenceline communities)
| Lead Author (Publication Year) | Country | Study Design | Level of Adjustment a | Survey Resolution | Petrochemical Activity | Exposed Population c | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Temporal | Spatial | Source of Exposure (N) | Proximity to Source (km) | Count (N) | Mean Age (Years) | Male (%) | Cases (N) | |||||||||
| UP | MID | DWN | LK | MM | HL | NHL | ||||||||||
| Axelsson (2010) [ | Sweden | Cohort | Low | 1994–2005 | Local | – | – | 4 | ≤ 2 | 2800 (b) | 0 to 65+ | 50 (b) | 10 | – | – | – |
| Barregard (2009) [ | Sweden | Cohort | Low | 1975–2004 | Local | 1 | – | – | ≤ 5 | 5000 | 0 to 65+ | 50 (b) | 33 | – | – | – |
| Beale (2010) [ | USA | Cohort | Moderate | 1973–2006 | Local | 5 | – | – | ≤ 2.5 | 27,100 (b) | 0 to 65+ | 100 | 145 | 52 | 34 | 184 |
| Beale (2010) [ | USA | Cohort | Moderate | 1973–2006 | Local | 5 | – | – | ≤ 2.5 | 26,900 (b) | 0 to 65+ | 0 | 100 | 35 | 30 | 141 |
| Bulat (2011) [ | Serbia | Cohort | Low | 2003–2008 | Local | 1 | – | 2 | ≤ 7.5 | 26,375 (a) | 41 (a) | 100 | 15 | – | 12 | 21 |
| Bulat (2011) [ | Serbia | Cohort | Low | 2003–2008 | Local | 1 | – | 2 | ≤ 7.5 | 39,828 (a) | 41 (a) | 0 | 15 | – | 7 | 14 |
| De Roos (2010) [ | USA | Case-Control | High | 1988–2000 | Subnational | 15 | – | 33 | ≤ 3.2 | 864 | 58 | 53 | – | – | – | 94 |
| Fazzo (2016) [ | Italy | Cohort | Low | 1999–2006 | Local | 2 | – | 1 | ≤ 3 | 101 | 0 to 65+ | 100 | 8 | 4 | 4 | 4 |
| Fazzo (2016) [ | Italy | Cohort | Low | 1999–2006 | Local | 2 | – | 1 | ≤ 3 | 37 | 0 to 65+ | 0 | 1 | 4 | 3 | 5 |
| García-Pérez (2015) [ | Spain | Case-Control | Moderate | 1990–2011 | National | – | – | 96 | ≤ 2.5 | 872 | < 15 | 58 | 44 | – | – | – |
| Linos (1991) [ | USA | Case-Control | High | 1980–1983 | Subnational | 29 | – | – | ≤ 3.2 | 33 | < 65 | 100 | 15 | – | – | 14 |
| Linos (1991) [ | USA | Case-Control | High | 1980–1983 | Subnational | – | – | 28 | ≤ 3.2 | 59 | < 65 | 100 | 27 | – | – | 18 |
| Lyons (1995) [ | UK | Cohort | Low | 1974–1991 | Local | – | – | 1 | ≤ 1.5 | 2632 | < 25 | 53 (b) | – | – | 2 | – |
| Pasetto (2012) [ | Italy | Cohort | Moderate | 1960–2000 | Local | 1 | – | – | ≤ 5 | 2419 | 53 | 100 | – | – | – | 11 |
| Pekkanen (1995) [ | Finland | Cohort | Low | 1983–1986 | Local | 1 | – | – | ≤ 8 | 1250 | 0 to 65+ | 51 | 2 | – | – | – |
| Salerno (2013) [ | Italy | Cohort | Low | 2003–2009 | Local | 1 | – | – | ≤ 3 | 3360 (b) | 0 to 65+ | 100 | 6 | 2 | 1 | 10 |
| Salerno (2013) [ | Italy | Cohort | Low | 2003–2009 | Local | 1 | – | – | ≤ 3 | 3160 (b) | 0 to 65+ | 0 | 6 | 6 | 1 | 10 |
| Sans (1995) [ | UK | Cohort | Moderate | 1974–1984 | Local | 1 | – | – | ≤ 7.5 | 23,650 | < 15 | 51 | 119 | – | – | – |
| Wilkinson (1999) [ | UK | Cohort | Low | 1974–1991 | National | 11 | – | – | ≤ 2 | 7070 (b) | < 15 | 51 (b) | 19 | – | 2 | 4 |
| Yu (2006) [ | Taiwan | Case-Control | High | 1997–2003 | Local | 4 | – | 5 | ≤ 3 | 25 | 20–29 | 53 | 14 | – | – | – |
| Zusman (2012) [ | Israel | Cohort | Low | 2000–2006 | Local | 1 | 1 | 1 | ≤ 0.5 | 14,050 | 30–64 (a) | 48 (a) | – | – | – | 9 |
| All Studies | – | – | – | – | – | – | – | – | – | 187,585 | – | – | 579 | 103 | 96 | 539 |
aLEVEL OF ADJUSTMENT | Low Typically adjusted for age and gender only, Moderate Adjusted for age, gender and at least one other demographic characteristic (i.e. income, ethnicity, or occupation); High Additionally adjusted for at least one lifestyle or genetic risk factor (i.e. BMI, smoking status, or family history)
bSOURCE OF EXPOSURE | UP Upstream (‘Refineries’), MID Midstream (‘Petrochemical Storage Facilities’), DWN Downstream (‘Petrochemical Plants’ and the ‘Organic Chemical Industry’)
cEXPOSED POPULATION | (a) = Author correspondence; (b) Estimated from the 1991 UK census, or the Global Rural-Urban Mapping Projects 30 arc-second grids (GRUMP v1, 2000)
dCASES | LK Leukaemia, MM Multiple Myeloma, HL Hodgkin Lymphoma, NHL Non-Hodgkin Lymphoma
Median annual emission rates for all petrochemical refineries in the United States. (Source: US-EPA Toxic Release Inventory 1987-2015 [64])
| Year(s) | Count | BTEX Emissions (tonnes per annum) | |||
|---|---|---|---|---|---|
| Benzene | Toluene | Ethylbenzene | Xylenes | ||
| 1987 | 144 | 6.19 | 15.88 | 2.37 | 8.94 |
| 2011–2015 | 145 | 2.90 | 5.14 | 1.00 | 4.24 |
Newcastle-Ottawa scale for assessing cohort study quality
| Lead Author (Publication Year) | Selection (Max = 4) | Comparability (Max = 2) | Exposure (Max = 3) | Overall Quality (Max = 9) |
|---|---|---|---|---|
| Axelsson (2010) [ | 3 | 1 | 2 | 6 |
| Barregard (2009) [ | 3 | 1 | 2 | 6 |
| Beale (2010) [ | 2 | 2 | 2 | 6 |
| Bulat (2011) [ | 3 | 1 | 1 | 5 |
| Fazzo (2016) [ | 3 | 1 | 1 | 5 |
| Lyons (1995) [ | 2 | 1 | 2 | 5 |
| Pasetto (2012) [ | 3 | 2 | 2 | 7 |
| Pekkanen (1995) [ | 2 | 1 | 1 | 4 |
| Salerno (2013) [ | 3 | 1 | 1 | 5 |
| Sans (1995) [ | 2 | 2 | 2 | 6 |
| Wilkinson (1999) [ | 2 | 2 | 2 | 6 |
| Zusman (2012) [ | 3 | 0 | 1 | 4 |
aStudies not included in the meta-analysis of leukaemia incidence
| Newcastle-Ottawa scale for assessing case-control study quality
| Lead Author (Publication Year) | Selection (Max = 4) | Comparability (Max = 2) | Exposure (Max = 3) | Overall Quality (Max = 9) |
|---|---|---|---|---|
| De Roos (2010) [ | 4 | 2 | 2 | 8 |
| García-Pérez (2015) [ | 2 | 1 | 3 | 6 |
| Linos (1991) [ | 3 | 2 | 2 | 7 |
| Yu (2006) [ | 3 | 2 | 1 | 6 |
a Studies not included in the meta-analysis of leukaemia incidence
Fig. 2The association between residential exposure to petrochemical activity and the relative risk (RR) of Leukaemia incidence
Pooled estimates on the relative risk (RR) of leukaemia incidence within 5 km of a petrochemical facility, moderated by different characteristics
| Assessment | Characteristics | Heterogeneity Tests | Pooled Relative Risks | ||
|---|---|---|---|---|---|
| I2 (%) | QE (p-value) c | QM (p-value) c | |||
| Base Model | – | 52.18 | 0.01 | – | – |
| Demographic | 1.1. Gender • All ( • Male ( • Female ( | 47.98 | 0.03 | 0.67 | – |
1.2. Participants • Children ( • General Population ( | 57.63 | 0.01 | 0.51 | – | |
| Diagnosis | 2.1. Classification Scheme • ICD 7–10 ( • ICD for Oncology ( | 49.48 | 0.02 | 0.37 | – |
2.2. Classification Scheme • ICD 7–8 ( • ICD 9–10 ( • ICD for Oncology ( | 56.71 | 0.02 | 0.73 | – | |
| Exposure | 3.1. Petrochemical Sector • Upstream ( • Downstream ( • Combination ( | 52.99 | 0.02 | 0.85 | – |
3.2. Maximum Distance • 3 km ( • 3.1 to 5 km ( | 41.98 | 0.05 | 0.12 | – | |
| Geography | 4. Continent • Europe ( • North America ( • Asia ( | 31.67 | 0.09 | 0.24 | – |
| Quality d | 5.1. Newcastle-Ottawa Score • Low ( • High ( | 45.10 | 0.04 | 0.07 | – |
5.1.1. Participant Selection • Low ( • High ( | < 0.01 | 0.60 | < 0.01 | Low: 1.01 [0.90 to 1.14] High: 1.58 [1.32 to 1.90] | |
5.1.2. Study Comparability • Low ( • High ( | 45.07 | 0.04 | 0.20 | – | |
5.1.3. Outcome Assessment • Low ( • High ( | 33.38 | 0.12 | 0.03 | Low: 1.71 [1.25 to 2.35] High: 1.15 [0.98 to 1.37] | |
| Temporal | 6.1. Study Start • 1965 to 1974 ( • 1975 to 1984 ( • 1985 to 1994 ( • 1995 to 2004 ( | < 0.01 | 0.42 | < 0.01 | 1965/74: 1.02 [0.91 to 1.15] 1975/84: 1.21 [1.09 to 1.34] 1985/94: 1.43 [1.23 to 1.65] 1995/04: 1.69 [1.36 to 2.11] 2005/14: 2.00 [1.48 to 2.70] b |
| 6.2. Study Start (+ 1 Year) a | < 0.01 | 0.28 | < 0.01 | 1971: 1.00 [0.88 to 1.14] 1981: 1.20 [1.09 to 1.33] 1991: 1.44 [1.23 to 1.69] 2001: 1.73 [1.36 to 2.22] 2011: 2.08 [1.48 to 2.93] b | |
| Mixed Effect | 5.1.1. Participant Selection, and 6.2 Study Start (+ 1 Year) a | < 0.01 | 0.63 | < 0.01 | 1971: 1.38 [1.02 to 1.87] 1981: 1.49 [1.21 to 1.84] 1991: 1.61 [1.34 to 1.93] 2001: 1.74 [1.36 to 2.22] 2011: 1.88 [1.32 to 2.67] b |
a Continuous variable
b Predicted risk
c Wald type Chi-Squared tests: Q Test for Residual Heterogeneity, Q Test of Moderators
d Newcastle-Ottawa Score: Total (L = 0–5, H = 6–9), Selection (L = 0–2, H = 3–4), Comparability (L = 0–1, H = 2), Assessment (L = 0–1, H = 2–3)
Fig. 3Meta-regression outputs, illustrating the relationship between Relative Risk (RR) of leukaemia incidence and the initial reporting year of each study, while controlling for study quality. The contour-enhance funnel plot is used to check for the impact of unpublished literature, and the significance of individual studies
Fig. 4The association between residential exposure to petrochemical activity and the relative risk (RR) of Non-Hodgkin’s Lymphoma incidence
Fig. 5The association between residential exposure to petrochemical activity and the relative risk (RR) of Hodgkin’s Lymphoma incidence
Fig. 6The association between residential exposure to petrochemical activity and the relative risk (RR) of Multiple Myeloma incidence
Estimated population attributable factor and Leukaemia Incidence cases for Louisiana residents living within 5 km of a petrochemical facility along the Mississippi River (2011–15)
| Parish Name | Population | Age-Adjusted Leukaemia Incidence (2011–15) | Population Attributable Fraction (%)** | Attributable Leukaemia Cases (2011–15) | |||
|---|---|---|---|---|---|---|---|
| Exposed (N) | Total (N) | Exposed (%) | Annual Cases Per 100,000 * | 5-Year Count (N) | |||
| (1) East Baton Rouge | 82,554 | 440,046 | 19% | 13.2 [11.7–14.8] | 290.4 [257.4–325.6] | 10% [6–14%] | 28.5 [14.6–47.0] |
| (2) Orleans | 37,360 | 343,573 | 11% | 11.2 [9.7–12.9] | 192.4 [166.6–221.6] | 6% [3–9%] | 11.4 [5.6–19.8] |
| (3) St. Bernard | 22,542 | 35,887 | 63% | 8.4 [4.8–13.5] | 15.1 [8.6–24.2] | 27% [17–36%] | 4.0 [1.4–8.8] |
| (4) St. Charles | 13,730 | 52,745 | 26% | 11.8 [7.9–16.9] | 31.1 [20.8–44.6] | 13% [8–19%] | 4.1 [1.6–8.5] |
| (5) Iberville | 13,223 | 33,387 | 40% | 14.0 [9.0–20.9] | 23.4 [15.0–34.9] | 19% [11–26%] | 4.4 [1.7–9.2] |
| (6) St. John the Baptist | 9796 | 45,914 | 21% | 12.0 [7.7–17.8] | 27.6 [17.7–40.9] | 11% [6–16%] | 3.0 [1.1–6.6] |
| (7) West Baton Rouge | 4553 | 23,774 | 19% | 13.9 [13.4–14.4] † | 16.5 [15.9–17.1] | 10% [6–15%] | 1.7 [0.9–2.5] |
| (8) Ascension | 1833 | 107,208 | 2% | 12.3 [9.2–15.9] | 65.9 [49.3–85.2] | 1% [1–2%] | 0.7 [0.3–1.3] |
| (9) St. James | 1519 | 22,100 | 7% | 13.9 [13.4–14.4] † | 15.4 [14.8–15.9] | 4% [2–6%] | 0.6 [0.3–0.9] |
| (10) Plaquemines | 940 | 23,031 | 4% | 13.9 [13.4–14.4] † | 16.0 [15.4–16.6] | 2% [1–4%] | 0.4 [0.2–0.6] |
| (11) Lafourche | 25 | 96,301 | < 0.1% | 15.3 [12.1–19.1] | 73.7 [58.3–92.0] | 0% [0–0%] | 0.0 [0.0–0.0] |
| (12) Jefferson | 0 | 432,415 | 0% | 13.6 [12.2–15.2] | 294.0 [263.8–328.6] | 0% [0–0%] | 0.0 [0.0–0.0] |
*Age-Adjusted Leukaemia Incidence rates obtained from by the National Cancer Institute (https://statecancerprofiles.cancer.gov/data-topics/incidence.html)
** Leukaemia Incidence relative risk (RR) = 1.58 [1.32–1.9]
†Use of the Louisiana State cancer rate, in parishes where incidence rates have been censored and conditions with a low occurrence (< 3 cases per annum)
Fig. 7Estimated cases of Leukaemia Incidence in Louisiana riverside parishes, which are attributable to residential exposure to the petrochemical industry (2011–15)